| Objective:This study aims to evaluate the efficacy of applying of Resina Draconis externally in the treatment of pressure injury through Meta-analysis,and to explore the mechanism and drug target of Resina Draconis in treating pressure injury by means of network pharmacology and molecular docking.Also,the mechanism and drug target of Compound Resina Draconis Capsule in treating coronary heart disease was explored through network pharmacology and molecular docking.This study is expected to provide a theoretical reference for the clinical use of Resina Draconis to treat the patients with pressure Injury and for the use of Compound Resina Draconis Capsule to treat coronary heart disease.Methods:All the literature on the external application of Resina Draconis to treat pressure injury was retrieved from CNKI,PubMed and other databases starting from the inception of these databases to December 2022.A Meta-analysis of the literature meeting the inclusion criteria was then conducted with the assistance of Review manager 5.3 software.Also,the risk of bias and the quality of literature were evaluated as well.The chemical components of Resina Draconis and Compound Resina Draconis Capsule(Resina Draconis,Pseudo-Ginseng,Borneol)were searched for from Traditional Chinese Medicine Systems Pharmacology Database.Swiss ADME platform and Swiss Target Prediction Database were used to screen the active components and achieve drug targets,while disease targets were obtained from Gene Cards and other databases.On this basis,the drug-component-disease target network and the protein-protein interaction(PPI)network were constructed.In addition,both gene ontology(GO)analysis and kyoto encyclopedia of genes and genomes(KEGG)pathway enrichment analysis were performed on the Metascape platform,with Autodock Vina software adopted to dock the core active components with the key targets.Results:(1)In total,1202 articles were retrieved for this study.According to the inclusion and exclusion criteria,22 articles were included.There were 1126 patients with pressure injury,including 576 cases in the experimental group and 550 cases in the control group.No significant difference was observed in the baseline data between these two groups.The total effective rate of Resina Draconis in the treatment of pressure injury was higher compared to conventional western medicine [OR=7.9,95%Cl(4.91,12.71),P<0.00001].Also,the healing time of pressure injury was shorter compared to the control group[OR=﹣6.92,95%CI(﹣9.84,﹣4.00),P<0.00001].(2)64 active components of Resina Draconis were screened and 90 targets were found to be related to pressure injury through network pharmacology.The drug-component-disease target network showed that the core active components of Resina Draconis in treating pressure injury included apigenin,7,4’-dihydroxy flavone,5,7,4’-trihydroxy-8-methyl flavone,resveratrol,7,4’-dihydroxy flavanone and so on.The PPI network showed that adrenergic receptor(AR),prostaglandin G/H synthase 2(PTGS2)and epidermal growth factor receptor(EGFR)may be the key targets of Resina Draconis in treating pressure injury.In addition,the results of GO analysis showed that the treatment of pressure injury by Resina Draconis mainly involves many significantly related biological processes,such as the response to external stimuli,the adjustment of body fluid level,and the adjustment to defense response.KEGG pathway enrichment analysis demonstrated that the treatment of pressure injury by Resina Draconis mainly involved arachidonic acid metabolism,phosphatidylinositol3-kinase-protein kinase B(PI3K-Akt)and other signal pathways.The results of molecular docking showed that the binding energy(Affinity)of most core active components of Resina Draconis with the key targets was lower than-5.5 kcal/mol,which indicates strong binding activity.(3)81 active components of Compound Resina Draconis Capsule were screened and 124 targets were found to be associated with coronary heart disease through network pharmacology.The drug-component-disease target network showed that the core active components of Compound Resina Draconis Capsule in treating coronary heart disease included quercetin,apigenin,7,4’-dihydroxy flavone,5,7,4’-trihydroxy-8-methyl flavone,7,4’-dihydroxy flavanone and so on.The PPI network showed that akt serine/threonine kinase 1(AKT1),EGFR,AR,PTGS2,steroid receptor coactivator(SRC),estrogen receptor α(ESR1)may be the key targets of Compound Resina Draconis Capsule in treating coronary heart disease.In addition,the results of GO analysis showed that the treatment of coronary heart disease by Compound Resina Draconis Capsule mainly involved many significantly related biological processes,such as the response to Inflammatory reaction,fatty acid metabolism,and the reaction to oxidative stress.The results of KEGG pathway enrichment analysis demonstrated that the treatment of coronary heart disease by Compound Resina Draconis Capsule mainly involved the signal pathway of peroxisome proliferator-activated receptor(PPAR),that of nuclear factor-κB(NF-κB),arachidonic acid metabolism and other signal pathways.The results of molecular docking showed that the core active components and key targets of Compound Resina Draconis Capsules had a lower affinity than-5.5 kcal/mol,which indicates strong binding activity.Conclusions:The total effective rate of applying Resina Draconis externally in treating pressure injury was higher compared to conventional western medicine,and the healing time of pressure injury was shorter compared to the control group,which suggests that the external application of Resina Draconis is a better choice in clinical practice.According to the results of this research,it can be predicted that apigenin,7,4’-dihydroxy flavone and other active components in Resina Draconis would combine with AR,PTGS2,EGFR and other targets to affect arachidonic acid metabolism,PI3K-Akt and other signaling pathways,which plays a role in treating pressure injury.Meanwhile,it is predicted that quercetin,resveratrol and other active components in Compound Resina Draconis Capsules would combine with AKT1,AR,PTGS2 and other targets to affect NF-κB,PPAR and other signal pathways,which facilitates the treatment of coronary heart disease. |
PDF Full Text Request